OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.725
-0.045 (-2.54%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
OS Therapies Incorporated
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 1, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Paul Romness |
Contact Details
Address: 15825 Shady Grove Road, Suite 135 Rockville, Maryland 20850 United States | |
| Phone | 410-297-7793 |
| Website | ostherapies.com |
Stock Details
| Ticker Symbol | OSTX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001795091 |
| Employer ID | 82-5118368 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert G. Petit Ph.D. | Chief Medical Officer and Chief Scientific Officer |
| Christopher P. Acevedo | Chief Financial Officer |
| Jack Doll | Chief of Staff |
| Gerald E. Commissiong | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 12, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 1, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 8-K | Current Report |
| Aug 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 22, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |